Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
immunomodulatory drug |
| gptkbp:CASNumber |
160898-65-7
|
| gptkbp:chemicalFormula |
C16H22N4O2
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developer |
gptkb:NewLink_Genetics
|
| gptkbp:hasInChIKey |
QXWJQKQZJODQKQ-GFCCVEGCSA-N
|
| gptkbp:hasSMILES |
CN1C=CC2=C1C=CC(=C2)C[C@@H](C(=O)O)N
|
| https://www.w3.org/2000/01/rdf-schema#label |
indoximod
|
| gptkbp:investigational_use |
immunotherapy
|
| gptkbp:mechanismOfAction |
IDO pathway inhibitor
|
| gptkbp:molecularWeight |
302.38 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103886
11327822 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:1-methyl-D-tryptophan
|
| gptkbp:target |
gptkb:indoleamine_2,3-dioxygenase_(IDO)
|
| gptkbp:therapeuticArea |
oncology
|
| gptkbp:UNII |
6QX8J75Z1C
|
| gptkbp:bfsParent |
gptkb:IDO1
|
| gptkbp:bfsLayer |
7
|